Nevro Corp. (NYSE:NVRO) Given Average Rating of "Reduce" by Analysts

Nevro Corp. (NYSE:NVRO - Get Free Report) has received a consensus recommendation of "Reduce" from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $6.43.

Several equities research analysts have commented on NVRO shares. Citigroup cut their price target on shares of Nevro from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Wednesday, December 11th. Canaccord Genuity Group raised their target price on shares of Nevro from $4.00 to $5.85 and gave the stock a "hold" rating in a research note on Friday, February 7th. Piper Sandler upgraded shares of Nevro from a "neutral" rating to an "overweight" rating and cut their price objective for the stock from $6.00 to $5.85 in a research report on Friday, February 7th. Robert W. Baird upped their price objective on Nevro from $5.00 to $6.00 and gave the company a "neutral" rating in a report on Tuesday, November 12th. Finally, JMP Securities reissued a "market perform" rating on shares of Nevro in a research report on Tuesday, November 12th.

Institutional Trading of Nevro

A number of institutional investors have recently bought and sold shares of the company. Intech Investment Management LLC acquired a new position in shares of Nevro during the third quarter valued at about $69,000. Charles Schwab Investment Management Inc. grew its stake in Nevro by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 303,675 shares of the medical equipment provider's stock valued at $1,698,000 after acquiring an additional 11,369 shares during the period. Quantbot Technologies LP grew its stake in Nevro by 1,290.4% in the third quarter. Quantbot Technologies LP now owns 14,418 shares of the medical equipment provider's stock valued at $81,000 after acquiring an additional 13,381 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Nevro by 171.3% during the third quarter. BNP Paribas Financial Markets now owns 135,145 shares of the medical equipment provider's stock valued at $755,000 after acquiring an additional 85,324 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Nevro by 130.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,000,000 shares of the medical equipment provider's stock worth $5,590,000 after purchasing an additional 566,462 shares during the period. Institutional investors own 95.52% of the company's stock.

Remove Ads

Nevro Stock Down 0.1 %

Nevro stock traded down $0.01 during midday trading on Monday, reaching $5.79. The stock had a trading volume of 637,581 shares, compared to its average volume of 664,322. Nevro has a 1-year low of $3.17 and a 1-year high of $15.98. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. The firm's fifty day simple moving average is $4.93 and its 200-day simple moving average is $4.94. The stock has a market capitalization of $216.78 million, a P/E ratio of -3.06 and a beta of 0.94.

Nevro (NYSE:NVRO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The medical equipment provider reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.15. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The company had revenue of $105.55 million for the quarter, compared to the consensus estimate of $102.61 million. As a group, analysts expect that Nevro will post -2.44 EPS for the current fiscal year.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.